**Shanghai Henlius Biotech, Inc.**
**上海復宏漢霖生物技術股份有限公司**
*(A joint stock company incorporated in the People's Republic of China with limited liability)*
**(Stock code: 2696)**

# INSIDE INFORMATION ANNOUNCEMENT

# AMENDMENTS TO LICENSE AGREEMENTS WITH ABBOTT AND KGBIO FOR HANSIZHUANG

## A. INTRODUCTION

This announcement is made by Shanghai Henlius Biotech, Inc. (the "**Company**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements issued by the Company dated 12 September 2019, 30 September 2019 and 25 August 2023 in relation to the entering into certain agreements (the "**Original KGBio License Agreements**") with PT Kalbe Genexine Biologics ("**KGBio**") for the exclusive license to develop and commercialise HANSIZHUANG (serplulimab injection) (the "**Licensed Product**") in the agreed Southeast Asia, Middle East and North African countries.

In December 2024, the Company entered into an agreement (the "**Original Abbott License Agreement**") with Abbott Products Operations AG ("**Abbott**") for, among others, the exclusive license to commercialise the Licensed Product in the agreed Latin America and Caribbean countries.

The board of directors of the Company hereby announces that on 24 February 2026, upon amicable negotiations between the parties, the Company entered into the Amendment and Partial Termination Agreement (the "**Amendment and Partial Termination Agreement to KGBio License Agreements**") with KGBio to terminate the exclusive license rights for the Licensed Product under the Original KGBio License Agreements in territories other than Indonesia (the "**KGBio Terminated Territories**").

On the same date, the Company entered into the amendments to the License Agreement (the "**Amendments to Abbott License Agreement**") with Abbott to amend certain terms under the Original Abbott License Agreement in relation to, among others, the licensed territory and milestone payments concerning the Licensed Product, so as to further expand the licensed territory concerning the Licensed Product under the Original Abbott License Agreement (including the KGBio Terminated Territories and other agreed countries or regions).

## B. PRINCIPAL TERMS OF THE AMENDMENTS TO ABBOTT LICENSE AGREEMENT

| | |
|---|---|
| **Additional Licensed Territories** | The agreed regions covering Asia, the Middle East, Africa and Eastern Europe (42 countries/regions in total). |
| **Additional milestone payments** | Abbott shall make additional payments to the Company as follows:<br><br>(a) regulatory milestone payments in respect of the Licensed Product of not more than US$46 million in aggregate based on achievements of each regulatory milestone of the Licensed Product in the Additional Licensed Territories; and<br><br>(b) commercial sales milestone payments in respect of the Licensed Product of not more than US$80 million in aggregate based on achievement of level of cumulative net sales of the Licensed Product in the Additional Licensed Territories. |

Save for the amendments mentioned above, the other principal terms of the Original Abbott License Agreement remain unchanged. Amendments to Abbott License Agreement shall take effect upon fulfillment of all stipulated conditions precedent which mainly include the execution of Amendment and Partial Termination Agreement to KGBio License Agreements between the Company and KGBio, related confirmation having been obtained by the Company from KGBio confirming that it has ceased related activities related to the Licensed Product in the KGBio Terminated Territories and the necessary rights having been acquired by the Company to grant Abbott the stipulated license.

## C. PRINCIPAL TERMS OF THE AMENDMENT AND PARTIAL TERMINATION AGREEMENT TO KGBIO LICENSE AGREEMENTS

Pursuant to the Amendment and Partial Termination Agreement to KGBio License Agreements, the Company shall terminate the exclusive license for the Licensed Product under the Original KGBio License Agreements in the KGBio Terminated Territories. KGBio shall transfer the marketing authorisations obtained within the KGBio Terminated Territories for the Licensed Product to the third party designated by the Company. The Company shall pay KGBio milestone payments of no more than US$33.75 million in aggregate in accordance with the transfer progress. The regulatory milestones agreed in the Original KGBio License Agreements shall be reduced accordingly. Following such amendments, the provisions under the Original KGBio License Agreements in relation to commercial sales milestones and royalties shall apply only to Indonesia.

## D. INFORMATION ABOUT THE LICENSED PRODUCT

HANSIZHUANG (serplulimab injection) is an innovative anti-PD-1 monoclonal antibody independently developed by the Company, which was approved for marketing in Chinese Mainland (excluding Hong Kong, Macau and Taiwan regions of China, same as below) for indications including the combination with chemotherapy for the first-line treatment of squamous non-small cell lung cancer (sq-NSCLC), extensive-stage small cell lung cancer (ES-SCLC), esophageal squamous cell carcinoma (ESCC) and non-squamous non-small cell lung cancer (nsq-NSCLC). Meanwhile, HANSIZHUANG was approved for marketing in the European Union, the United Kingdom, Indonesia, Cambodia, Thailand, Malaysia, Singapore, India and other countries/regions respectively, and has been granted Orphan-drug Designation by drug administrations in the United States, the European Union, Switzerland, South Korea and other countries/regions, respectively. In addition, the Company is in the process of advancing a number of clinical studies of HANSIZHUANG and related combination therapies globally, covering a wide range of indications such as lung cancer, esophageal carcinoma, head and neck squamous cell carcinoma, colorectal cancer and gastric cancer. In December 2025, the drug registration application of HANSIZHUANG in combination with chemotherapy for neo-/adjuvant treatment for gastric cancer has been accepted by the National Medical Products Administration (NMPA), and has been granted the procedure for priority review.

The sales promotion of HANSIZHUANG in Chinese Mainland is conducted by the Company's inhouse commercialisation team. As of the date of this announcement, the Company has entered into business partnerships with multiple internationally renowned partners for commercialisation of HANSIZHUANG in over 100 countries and regions worldwide.

According to the information provided by IQVIA MIDAS™ (IQVIA is a global provider of professional information and strategic consulting services in the pharmaceutical and healthcare industry), the worldwide sales of monoclonal antibody drugs targeting PD-1 amounted to approximately US$45.7 billion in 2024.

## E. BENEFITS OF THE AMENDMENTS TO THE AGREEMENTS

Upon amicable negotiations between the parties, the Company terminated the collaboration with KGBio in relation to the commercialisation of the Licensed Product in the KGBio Terminated Territories, and granted Abbott the exclusive rights to commercialise the Licensed Product in the Additional Licensed Territories including the KGBio Terminated Territories and other agreed countries or regions. The Company has previously established a good cooperative relationship with Abbott for the commercialisation of multiple products across various regions globally. The expansion of the collaboration with Abbott on the commercialisation of the Licensed Product in the Additional Licensed Territories will help better promote the overseas market expansion of the Licensed Product, and strengthen the accessibility and international recognition of the Company's products.

## F. INFORMATION ABOUT ABBOTT

Abbott is a wholly-owned subsidiary of Abbott Laboratories which is listed on the New York Stock Exchange (stock code: ABT). Abbott Laboratories's business are primarily in the fields of diagnosis, medical devices, nutrition, and medicinal products.

## G. INFORMATION ABOUT KGBIO

KGBio is a holding subsidiary of PT Kalbe Farma Tbk, which is listed on the Indonesia Stock Exchange (stock code: KLBF). PT Kalbe Farma Tbk's primary business divisions are prescription pharmaceutical, consumer health, nutritionals, distribution and logistic.

On behalf of the Board
**Shanghai Henlius Biotech, Inc.**
**Wenjie Zhang**
*Chairman*

Hong Kong, 24 February 2026

*As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as the chairman and non-executive director, Dr. Jun Zhu as the executive director, Mr. Qiyu Chen, Mr. Yuqing Chen, Ms. Xiaohui Guan, Dr. Yi Liu and Dr. Xingli Wang as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Ruilin Song and Mr. Yihao Zhang as the independent non-executive directors.*